



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

19th October, 2026

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

VENKAT
RAMESH
CHEKURI

Digitally signed by
VENKAT RAMESH
CHEKURI
Date: 2026.10.19
14:12:38 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India



NATCO announces launch of Carboplatin Injection (generic of Paraplatin®) in the U.S. market

Hyderabad, India, October 19th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announces launch of Carboplatin Injection, a generic version of Paraplatin® in the U.S. market by its U.S. subsidiary NATCO Pharma USA LLC. NATCO launches this product in manufacturing collaboration with Teyro Labs Pvt Ltd, based in Chennai. This launch helps address a critical shortage of the product in the U.S. market.

Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. Please refer to the full Prescribing Information for complete indications, limitations, and important safety information.

Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for 12 months ending June'26 as per industry sales data.

****Safe Harbor Statement***

All brand names and trademarks are the property of their respective owners

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies in domestic market and focuses on limited competition molecules in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information or queries on the press release please contact:

Rajeev Menon – Investor Relations
Email: r.menon@natcopharma.co.in

Tel: 040-23547532 / Ext – 323